View in EDS

New landscape of the diagnosis of Alzheimer's disease.

Saved in:
Bibliographic Details
Title: New landscape of the diagnosis of Alzheimer's disease.
Authors: Frisoni, Giovanni B (AUTHOR), Hansson, Oskar (AUTHOR), Nichols, Emma (AUTHOR), Garibotto, Valentina (AUTHOR), Schindler, Suzanne E (AUTHOR), van der Flier, Wiesje M (AUTHOR), Jessen, Frank (AUTHOR), Villain, Nicolas (AUTHOR), Arenaza-Urquijo, Eider M (AUTHOR), Crivelli, Lucia (AUTHOR), Fortea, Juan (AUTHOR), Grinberg, Lea T (AUTHOR), Ismail, Zahinoor (AUTHOR), Minoshima, Satoshi (AUTHOR), Ossenkoppele, Rik (AUTHOR), Zetterberg, Henrik (AUTHOR), Petersen, Ronald C (AUTHOR), Dubois, Bruno (AUTHOR)
Source: Lancet. 9/27/2025, Vol. 406 Issue 10510, p1389-1407. 19p.
Subjects: Alzheimer's disease, Diagnosis, Biomarkers, Cognition disorders, Positron emission tomography, Amyloid beta-protein, Medical care
Abstract: Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis—a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis—a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide. [ABSTRACT FROM AUTHOR]
ISSN:01406736
DOI:10.1016/S0140-6736(25)01294-2